Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cohance LifesciencesBOM:543064 -0.07%87 Pretax Margin % is 3.22% as of Mar. 2026, which is 92% below its 10-year median of 42.39. GuruFocus rates BOM:543064 with a GF Score™ of 87/100 and a GF Value™ of ₹695.81 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Cohance Lifesciences ranks better than 55.88% on this metric.
The historical rank and industry rank for Cohance Lifesciences's Pretax Margin % or its related term are showing as below:
BOM:543064'
s Pretax Margin % Range Over the Past 10 Years
Min: 9.13 Med: 42.39 Max: 51.08
Current: 9.13
BOM:543064's Pretax Margin % is ranked better than 55.88% of 961
companies
in the Drug Manufacturers industry
Industry Median: 7.06
vs BOM:543064: 9.13
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Cohance Lifesciences Pretax Margin % Related Terms
Cohance Lifesciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cohance Lifesciences (BOM:543064) has a Pretax Margin % of 3.22% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cohance Lifesciences and its competitors. This is 92% below median its historical median of 42.39. Over the past decade, Cohance Lifesciences' Pretax Margin % has ranged from 9.13 to 51.08. According to the industry distribution chart, Cohance Lifesciences ranks #424 out of 961 companies in the Drug Manufacturers industry, placing it in the top 44.1%.
Is Cohance Lifesciences' Pretax Margin % too high?
Cohance Lifesciences' current Pretax Margin % of 3.22% is 92% below median its 10-year median of 42.39. Over the past 10 years, this metric has ranged from a low of 9.13 to a high of 51.08. The Drug Manufacturers industry median Pretax Margin % is 7.06. Cohance Lifesciences' value of 3.22% is 54.4% below this industry median. Based on the distribution chart, Cohance Lifesciences ranks #424 out of 961 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cohance Lifesciences has a GF Score™ of 87/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cohance Lifesciences' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cohance Lifesciences ranks #424 out of 961 companies for Pretax Margin %. This puts Cohance Lifesciences in the upper half of its industry. The industry median Pretax Margin % is 7.06. Cohance Lifesciences' value of 3.22% is 54.4% below this benchmark. Historically, Cohance Lifesciences' own Pretax Margin % has ranged from 9.13 to 51.08 over the past decade. While the company's 10-year median is 42.39 vs. the industry median of 7.06, Cohance Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.06, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cohance Lifesciences's current Pretax Margin % of 3.22% is 54.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Cohance Lifesciences and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cohance Lifesciences's current Pretax Margin % is 3.22%, which is 92% below median its own 10-year median of 42.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cohance Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Cohance Lifesciences (BOM:543064) is currently considered Possible Value Trap. The stock's GF Value™ is ₹695.81, compared to a current price of ₹425.40 — trading 38.9% below its estimated fair value. The current Pretax Margin % is 3.22%, which is 92% below median its 10-year median of 42.39 and 54.4% below the Drug Manufacturers industry median of 7.06. Cohance Lifesciences' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Cohance Lifesciences (BOM:543064), the current Pretax Margin % is 3.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81.
GuruFocus considers Cohance Lifesciences to be Possible Value Trap.
Key valuation signals for BOM:543064:
Pretax Margin %: 3.22% (92% below median its 10-year median of 42.39)
GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
Industry Position: 54.4% below the Drug Manufacturers median (#424 of 961)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score
Get the complete analysis for BOM:543064
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
